NCT04002596 (TDPD) is a NA clinical trial of ExAblate Neuro Thalamotomy Treatment in Parkinson Disease, sponsored by InSightec.

Who is sponsoring NCT04002596?

NCT04002596 is sponsored by InSightec.

What drugs are being tested in NCT04002596?

Interventions in NCT04002596: ExAblate Neuro Thalamotomy Treatment.

What condition does NCT04002596 study?

NCT04002596 studies Parkinson Disease.

Is NCT04002596 still recruiting?

NCT04002596 is currently completed. Last updated 31 December 2025.

Last reviewed 2025-12-31 · How we verify

NCT04002596: TDPD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Initial Effectiveness of Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease

Completed NA Last updated 31 December 2025

What this trial tests

NA trial testing ExAblate Neuro Thalamotomy Treatment in Parkinson Disease in 10 participants. Completed in 4 September 2019.

Timeline

6 February 2017

Primary endpoint
5 December 2018

4 September 2019

Quick facts

Lead sponsor	InSightec
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	6 February 2017
Primary completion	5 December 2018
Estimated completion	4 September 2019
Sites	1 location across Japan

Drugs / interventions tested

ExAblate Neuro Thalamotomy Treatment

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

InSightec — full company profile →

Who can join

30 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Safety and Effectiveness in ExAblate Neuro treatment of medication-refractory tremor in subjects with idiopathic Parkinson's disease.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel targeted therapies for Parkinson's disease.
Ntetsika T, Papathoma PE, Markaki I. · · 2021 · cited 78× · PMID 33632120 · DOI 10.1186/s10020-021-00279-2
Focused ultrasound thalamotomy for tremor treatment impacts the cerebello-thalamo-cortical network.
Dahmani L, Bai Y, Li M, Ren J, et al · · 2023 · cited 16× · PMID 37322044 · DOI 10.1038/s41531-023-00543-8
Targeted manipulation of pain neural networks: The potential of focused ultrasound for treatment of chronic pain.
Todd N, McDannold N, Borsook D. · · 2020 · cited 13× · PMID 32534900 · DOI 10.1016/j.neubiorev.2020.06.007
Parkinson's disease as a somato-cognitive action network disorder.
Ren J, Zhang W, Dahmani L, Gordon EM, et al · · 2026 · cited 3× · PMID 41639440 · DOI 10.1038/s41586-025-10059-1

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other InSightec trials

Trials by the same sponsor.

NCT04667715 — Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma · NA · withdrawn
NCT05539196 — A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advance · recruiting
NCT05089786 — Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) · NA · unknown
NCT05565443 — MR-guided Focused Ultrasound Plus GCase · NA · recruiting
NCT05317858 — Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04002596 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InSightec
Last refreshed: 31 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04002596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing